BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10632351)

  • 1. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients.
    De Laurentiis M; De Placido S; Bianco AR; Clark GM; Ravdin PM
    Clin Cancer Res; 1999 Dec; 5(12):4133-9. PubMed ID: 10632351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.
    Neri A; Marrelli D; Roviello F; De Stefano A; Guarnieri A; Pallucca E; Pinto E
    Ann Surg Oncol; 2005 Mar; 12(3):246-53. PubMed ID: 15827817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
    Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
    Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks.
    Jerez JM; Franco L; Alba E; Llombart-Cussac A; Lluch A; Ribelles N; Munárriz B; Martín M
    Breast Cancer Res Treat; 2005 Dec; 94(3):265-72. PubMed ID: 16254686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting distant dissemination in patients with early breast cancer.
    Arriagada R; Rutqvist LE; Johansson H; Kramar A; Rotstein S
    Acta Oncol; 2008; 47(6):1113-21. PubMed ID: 18607866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of nodal involvement and survival analysis in breast cancer patients using image cytometric data: statistical, neural network and fuzzy approaches.
    Seker H; Odetayo MO; Petrovic D; Naguib RN; Bartoli C; Alasio L; Lakshmi MS; Sherbet GV
    Anticancer Res; 2002; 22(1A):433-8. PubMed ID: 12017328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence in breast cancer. Analysis with frailty model.
    Gohari MR; Mahmoudi M; Mohammed K; Pasha E; Khodabakhshi R
    Saudi Med J; 2006 Aug; 27(8):1187-93. PubMed ID: 16883450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
    Kattan MW; Giri D; Panageas KS; Hummer A; Cranor M; Van Zee KJ; Hudis CA; Norton L; Borgen PI; Tan LK
    Cancer; 2004 Dec; 101(11):2509-15. PubMed ID: 15495180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.